行情

ALDR

ALDR

Alder生物制药
NASDAQ

实时行情|Nasdaq Last Sale

18.70
+0.20
+1.08%
已收盘, 17:40 09/17 EDT
开盘
18.50
昨收
18.50
最高
18.82
最低
18.50
成交量
1,465.22万
成交额
--
52周最高
18.88
52周最低
8.39
市值
15.64亿
市盈率(TTM)
-4.1992
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALDR 新闻

  • 德意志银行:年底标普500将大跌13%至2600点
  • 新浪财经综合.3小时前
  • 欧洲8月份汽车销量大幅下滑 行业困境加剧
  • 新浪财经综合.3小时前
  • “脸书”新设独立监督委员会 可否决扎克伯格意见
  • 中国新闻网.4小时前
  • 德国8月纯电动汽车销量同比飙升逾一倍
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

ALDR 简况

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
展开

Webull提供Alder Biopharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。